{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"3.48","value":"3.0"},{"groupId":"OG001","spread":"3.62","value":"3.1"},{"groupId":"OG002","spread":"2.13","value":"3.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"118"},{"groupId":"OG002","value":"60"}],"units":"Participants"}],"description":"Amount of RBC transfusions for 8-week interval was defined as the total number of RBC transfusion units in a given 8-week interval during study. The best 8-week interval is a post-baseline 8-week interval where the participant had the fewest post-Study Day 1 RBC transfusion units. A valid 8-week period must start before the date of last dose of study drug + 30 days or end of treatment (EOT) visit whichever occurs first and ends before the first transfusion in post-treatment follow-up or the first day of subsequent anti-cancer therapy whichever occurs first.","dispersionType":"Standard Deviation","groups":[{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first. Dose escalation to 9.4 mg/kg was allowed before Protocol Amendment 2.","id":"OG000","title":"Phase 2: Imetelstat Sodium"},{"description":"Imetelstat sodium administered IV, at a starting dose of 7.5 mg/kg, every 4 weeks (on a 28-day cycle) until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.","id":"OG001","title":"Phase 3: Imetelstat Sodium"},{"description":"Imetelstat sodium-matching placebo administered IV, every 4 weeks (on a 28-day cycle), until death, lost to follow-up, withdrawal of consent, or study termination whichever occurs first.","id":"OG002","title":"Phase 3: Placebo"}],"paramType":"MEAN","populationDescription":"Phase 2: All Treated Analysis Set included all participants who received at least one dose of study drug.\n\nPhase 3: ITT Analysis Set included all participants randomized into the Phase 3 study.","reportingStatus":"POSTED","timeFrame":"Up to 5 years in Phase 2 and up to 3.7 years in Phase 3","title":"Phase 2 and Phase 3: Amount of RBC Transfusions in the Best 8-week Interval","type":"SECONDARY","unitOfMeasure":"number of RBC transfusions units"}